Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1746

Similar articles for PubMed (Select 18020538)

1.
2.
3.

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

Simpson KN, Jones WJ, Rajagopalan R, Dietz B.

Clin Drug Investig. 2007;27(7):443-52. Erratum in: Clin Drug Investig. 2007;27(8):564.

PMID:
17563124
4.
5.

Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.

Simpson KN, Rajagopalan R, Dietz B.

Adv Ther. 2009 Feb;26(2):185-93. doi: 10.1007/s12325-008-0141-8. Epub 2009 Feb 14.

PMID:
19219410
6.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
7.

Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

Broder MS, Chang EY, Bentley TG, Juday T, Uy J.

J Med Econ. 2011;14(2):167-78. doi: 10.3111/13696998.2011.554932. Epub 2011 Feb 2. Erratum in: J Med Econ. 2011;14(4):410.

PMID:
21288058
8.

Comparison of Markov model and discrete-event simulation techniques for HIV.

Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R.

Pharmacoeconomics. 2009;27(2):159-65. doi: 10.2165/00019053-200927020-00006.

PMID:
19254048
9.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
10.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000.

PMID:
21182347
11.

Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.

Simpson KN, Baran RW, Kirbach SE, Dietz B.

Value Health. 2011 Dec;14(8):1048-54. doi: 10.1016/j.jval.2011.06.011. Epub 2011 Nov 6.

PMID:
22152173
12.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
13.

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

Foglia E, Bonfanti P, Rizzardini G, Bonizzoni E, Restelli U, Ricci E, Porazzi E, Scolari F, Croce D.

PLoS One. 2013;8(2):e57777. doi: 10.1371/journal.pone.0057777. Epub 2013 Feb 27. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/e57d7e73-826c-4e1c-a7c6-d2c32d3809af.

14.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
15.

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, McLaren C.

AIDS. 2006 Mar 21;20(5):711-8.

PMID:
16514301
16.

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

Ribera E, Azuaje C, Lopez RM, Diaz M, Feijoo M, Pou L, Crespo M, Curran A, Ocaña I, Pahissa A.

AIDS. 2006 May 12;20(8):1131-9.

PMID:
16691064
17.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
18.

Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.

Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, Redfield RR.

AIDS Patient Care STDS. 2006 Nov;20(11):745-59.

PMID:
17134349
19.

[Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].

Smets E, Brogan AJ, Hill A, Adriaenssen I, Sawyer AW, Domingo-Pedrol P, Gostkorzewicz J, Ledesma F.

Enferm Infecc Microbiol Clin. 2013 Aug-Sep;31(7):430-6. doi: 10.1016/j.eimc.2012.11.001. Epub 2012 Dec 20. Spanish.

PMID:
23260386
20.

[Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].

Escobar I, Pulido F, Pérez E, Arribas JR, García MP, Hernando A.

Enferm Infecc Microbiol Clin. 2006 Oct;24(8):490-4. Spanish.

PMID:
16987465
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk